GADD45B and esophageal squamous cell carcinoma: Studies have reported that sulforaphene might have a potential in inhibiting the progression of ESCC by activating the GADD45B-MAP2K3-P38-p53 signaling pathway [31], indicating the possibility to improve the therapeutic effect of ESCC patients with aberrant ZNF154 methylation through epigenetic editing combined with targeted drugs like sulforaphene.